Clinical Investigation of Efficacy and Safety in Second-line Bevacizumab treatment combined with FOLFIRI or FOLFOX for metastatic colorectal cancer

Clinical Investigation of Efficacy and Safety in Second-line Bevacizumab treatment combined with FOLFIRI or FOLFOX for metastatic colorectal cancer - Clinical Investigation of Bevacizumab plus FOLFIRI or FOLFOX in previously treated metastatic colorectal cancer (2nd-BV)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001547

Enrollment

400

Registered

2008-12-03

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically confirmed adenocarcinoma in colon cancer, rectal cancer or cecal cancer 2)Unresectable and/or metastatic cancer 3)FOLFIRI+bevacizumab or FOLFOX+bevacizumab treatment in patients with previous chemotherapy 4)Performance status 0-2(ECOG)

Exclusion criteria

Exclusion criteria: 1)Prior bevacizumab administration 2)FOLFIRI+bevacizumab in patients with previous CPT-11-based chemotherapy, or FOLFOX+bevacizumab in patients with previous L-OHP-based chemotherapy

Design outcomes

Primary

Measure	Time frame
Response rate, Time to Treatment failure, Adverse events rate, Progression free survival, Overall survival	—

Countries

Japan

Contacts

Public ContactToshikazu Moriwaki

University of Tsukuba Gastroenterology

Outcome results